
Please try another search
Sumitomo Pharma Co., Ltd. engages in manufacture, and purchase and sale of pharmaceutical products for medical treatment in Japan, North America, and Asia. The company offers therapeutic agents for parkinson’s disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. It also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. Further, the company offers veterinary drugs, medical devices, etc. It has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
Name | Age | Since | Title |
---|---|---|---|
Toru Kimura | 64 | 2016 | Representative Director, President & CEO |
Tsutomu Nakagawa | - | 2023 | Managing Executive Officer & Director |
Motoyuki Sakai | 64 | 2024 | Rep. Dir., EVP of Glob. Corp. Strat., Glob. Fin. Admin. Ext. Aff., Corp. Gov., IT Mngt. & Data Anly. |
Yoshio Iteya | 69 | 2018 | Outside Audit & Supervisory Board Member |
Hisayoshi Kashima | - | 2014 | Full-Time Audit & Supervisory Board Member |
Mayumi Mochizuki | 71 | 2021 | Outside Audit & Supervisory Board Member |
Daishiro Michimori | 69 | 2022 | Outside Audit & Supervisory Board Member |
Hiroshi Niinuma | 67 | 2024 | Director |
Minoru Usui | 70 | 2021 | Independent Outside Director |
Koji Fujimoto | 62 | 2022 | Independent Outside Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review